Quadriplegia Treatment Market - Global Industry Analysis

Quadriplegia Treatment Market By Treatment Type (Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Anticonvulsants, Narcotic Analgesics, Antispasmodics & Muscle Relaxants, and Antibiotics), By Route of Administration (Oral, Intravenous, and Others), By Distribution Channel (Online Stores, Drug Stores, Retail Pharmacies, and Hospital Pharmacies), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 14-Jun-2022 Category: Healthcare Report Format : PDF Pages: 207 Report Code: ZMR-7001 Status : Published

The global quadriplegia treatment market is projected to grow with a compound annual growth rate (CAGR) of approximately 4.2 percent during the forecast period.

Description

Industry Prospective:

The global quadriplegia treatment market is projected to grow with a compound annual growth rate (CAGR) of approximately 4.2 percent during the forecast period. This global report covers key elements such as the quadriplegia treatment market’s drivers, restraints, and challenges, with their impacts on the treatment demands during the projection period. In addition, the report discovers significant opportunities in the quadriplegia treatment market.

Quadriplegia Treatment Market: Overview

Quadriplegia is a disorder in which both legs & arms become paralyzed and lose their ability to move normally. This condition, sometimes known as tetraplegia, is a symptom of a few multiple different underlying causes. Quadriplegia comes in a variety of forms, one with its particular set of symptoms and effects on the body. Quadriplegia can be transitory (meaning muscular control recovers) or permanent (meaning the paralysis does not lessen) based on the underlying reason. Quadriplegia treatment methods differ depending on what is generating the weakening in the first place.

Global Quadriplegia Treatment Market

COVID-19 Impact:

The global quadriplegia treatment market was moderately hampered by the outbreak of COVID-19. Most of the hospitals, clinics, and specialty clinics were focused on treating COVID-infected patients. This has directly affected the growth of the market. Most of the patients delayed their treatment or avoid hospital stays to stay away from COVID infection. This has reduced the treatment frequency for quadriplegia and ultimately reduced market revenue.

Quadriplegia Treatment Market: Growth Drivers

Growing prevalence of spinal cord injury propels the market growth

Quadriplegia is caused by damage to the spinal cord that occurs as a result of trauma to the base of the skull or the neck. Quadriplegia is caused by a variety of factors including paralysis following spinal tumors, accidents, and other spinal disorders. A spinal cord injury can result in half or complete limb paralysis. It is been reported that every year, approximately 250,000 -500,000 people worldwide have a spinal cord injury. The majority of these occurrences are the result of avoidable factors such as car accidents and violence. Annually, around 17,000 instances of spinal cord injury are reported in the United States, with an estimated 282,000 people living with the condition. Such a huge burden of disease is estimated to boost the demand for quadriplegia treatment, thereby driving the market growth. In addition to this, high spending power and heavy investment in the development of healthcare infrastructure are also estimated to fuel the market growth.

Quadriplegia Treatment Market: Restraints

High costs associated with the treatment hinder the market growth

The least frequent kind of spinal cord damage, complete quadriplegia, is also the most severe. Quadriplegia can have tremendous long-term costs. In general, it varies based on the patient's age. The cost of total quadriplegia during the first year itself is estimated to be $1,064,716. Quadriplegia costs approximately $184,891 each year for the rest of the patient's life. A catastrophic injury case, on the other hand, might ask for much more, because these statistics don't account for the patient's mental anguish, suffering & pain, decreased earning ability, and lost income. Thus, such a high cost of quadriplegia treatment may hamper the growth of the market.

Quadriplegia Treatment Market: Opportunities

Technological advancements in the medical field are likely to spur the market growth

Technical advances and a range of R&D activities in the domain of quadriplegia therapy will be two of the major drivers driving the global quadriplegia treatment market in the coming years. Patients with spinal injuries have become more aware of the many therapeutic options available to assist them in overcoming their challenges. Further, major players are investing heavily in drug discovery and development for innovative & effective treatment. All these factors collectively are predicted to create numerous opportunities for the growth of the market during the forecast period.

Quadriplegia Treatment Market: Challenges.

Strict regulatory bodies pose a challenge to market growth

A strong regulatory framework in different countries for the approval and marketing of the drugs used for quadriplegia treatment may pose a major challenge to market expansion. The FDA has a strict regulatory structure that must be adhered to by all market players. With defined regulatory requirements, most new businesses encounter safety, quality, and effectiveness challenges. As a result, regulatory bodies are the most significant impediment to newcomers entering the quadriplegia treatment market.

Quadriplegia Treatment Market: Segmentation

The global quadriplegia treatment market is bifurcated into treatment type, distribution channel, route of administration, and region. Based on the treatment type, the global market is divided into corticosteroids, antibiotics, antispasmodics & muscle relaxants, narcotic analgesics, anticonvulsants, antidepressants, and non-steroidal anti-inflammatory drugs (NSAIDs). The distribution channel segment consists of online stores, drug stores, retail pharmacies, and hospital pharmacies. By route of administration, the market is classified into Intravenous, oral, and others.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Recent Developments

  • In August 2021, Roche introduced an oral therapy for adults and children with Spinal Muscular Atrophy (SMA) (SMA). It's called Evrysdi, and it's the first and only medication for SMA patients in India.
  • In August 2021, Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) received a Fast Track Designation for MT-3921 for the treatment of spinal cord injury from the FDA.

Quadriplegia Treatment Market: Regional Landscape

North America dominates the market for quadriplegia treatment

Among the regions, North America is estimated to dominate the global quadriplegia treatment market and is expected to retain its dominance during the forecast period. The US is predicted to hold the largest market share owing to advanced technologies and growing awareness regarding different treatment options for quadriplegia. Europe is projected to hold the second-most position in the market owing to major research institutes. Asia Pacific is projected to be the most lucrative market during the forecast period and is anticipated to grow at the highest CAGR value.

Quadriplegia Treatment Market: Competitive Landscape

Major players functioning in the global quadriplegia treatment market include GlaxoSmithKline, Hoffmann La Roche, Zydus Cadila, Baxter International, Sanofi Pharmaceuticals, Merck & Co., Eli Lily & Co., Bristol Myers Squibb Co., Johnson & Johnson, Cipla, and AstraZeneca.

Global quadriplegia treatment market is segmented as follows:

By Treatment Type

  • Corticosteroids
  • Non- Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Antidepressants
  • Anticonvulsants
  • Narcotic Analgesics
  • Antispasmodics & Muscle Relaxants
  • Antibiotics

By Route of Administration

  • Oral
  • Intravenous
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Quadriplegia is caused by damage to the spinal cord that occurs as a result of trauma to the base of the skull or the neck. Quadriplegia is caused by a variety of factors including paralysis following spinal tumors, accidents, and other spinal disorders. A spinal cord injury can result in half or complete limb paralysis. It is been reported that every year, approximately 250,000 -500,000 people worldwide have a spinal cord injury. The majority of these occurrences are the result of avoidable factors such as car accidents and violence Annually, around 17,000 instances of spinal cord injury are reported in the United States, with an estimated 282,000 people living with the condition. Such a huge burden of disease is estimated to boost the demand for quadriplegia treatment, thereby driving market growth.

According to the Zion Market Research report, the global quadriplegia treatment market is predicted to grow with a compound annual growth rate (CAGR) of around 4.2 percent over the forecast period.

Among the regions, North America is estimated to dominate the global quadriplegia treatment market and is expected to retain its dominance during the forecast period. The US is predicted to hold the largest market share owing to advanced technologies and growing awareness regarding different treatment options for quadriplegia.

Major players functioning in the global quadriplegia treatment market include GlaxoSmithKline, Hoffmann La Roche, Zydus Cadila, Baxter International, Sanofi Pharmaceuticals, Merck & Co., Eli Lily & Co., Bristol Myers Squibb Co., Johnson & Johnson, Cipla, and AstraZeneca.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed